FCGR3A and FGL2 are highly expressed in elderly individuals (Supplementary Figure 2D), glioblastoma patients (G4) (Figure 1C), those with tumor progression after initial treatment (Figure 1D), and those with poor prognosis confirmed by OS, DSS and PDI (Figure 1E). Here, FCGR3A is linked to neoplasm.